Unum Therapeutics Inc. (UMRX): Price and Financial Metrics


Unum Therapeutics Inc. (UMRX)

Today's Latest Price: $0.69 USD

0.02 (2.37%)

Updated Dec 6 6:55pm

Add UMRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UMRX Stock Summary

  • Unum Therapeutics Inc's stock had its IPO on March 29, 2018, making it an older stock than only 3.05% of US equities in our set.
  • Of note is the ratio of Unum Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 8.79% of US stocks have a lower such ratio.
  • The volatility of Unum Therapeutics Inc's share price is greater than that of 94.87% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Unum Therapeutics Inc are ARDS, NVAX, PTI, MGNX, and PLX.
  • UMRX's SEC filings can be seen here. And to visit Unum Therapeutics Inc's official web site, go to www.unumrx.com.
UMRX Daily Price Range
UMRX 52-Week Price Range

UMRX Stock Price Chart More Charts


UMRX Price/Volume Stats

Current price $0.69
Prev. close $0.67
Day low $0.67
Day high $0.71
50-day MA $1.16
200-day MA $2.51
52-week high $6.64
52-week low $0.58
Volume 386,500
Avg. volume 148,206
Dividend yield N/A
Market Cap 21.16M

Unum Therapeutics Inc. (UMRX) Company Bio


Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company’s product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is based in Cambridge, Massachusetts.





UMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

UMRX Latest Social Stream


Loading social stream, please wait...

View Full UMRX Social Stream

UMRX Price Returns

1-mo -45.24%
3-mo -65.50%
6-mo -74.54%
1-year -88.27%
3-year N/A
5-year N/A
YTD -84.32%
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7523 seconds.